Acute myocardial infarction and cardiogenic shock

Prondzinsky R, Lemm H, Swyter M et al (2010) Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 38:152–160

Hochman JS, Sleeper LA, Webb JG et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341:625–634

Ruiz-Bailen M, Rucabado-Aguilar L, Exposito-Ruiz M et al (2009) Cardiogenic shock in acute coronary syndrome. Med Sci Monit 15: RA57–66

Goldberg RJ, Spencer FA, Gore JM et al (2009) Thirty-year trends (1975–2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 119:1211–1219

Théroux P, Armstrong PW, Mahaffey KW et al (2005) Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 26:1964–1970

Hon-KanYip, Ali A Youssef, Li-Teh Chang et al (2007) Association of Interleukin-l0 level with increased 30-day mortality in patients with ST-Segmen elevation acute myocardial infarction undergoing primary coronary intervention. Circ J 71:1086–1091

Tan J, Hua Q, Li J, Fan Z (2009) Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial infarction. Heart Vessels 24:329–334

Debrunner M, Schuiki E, Minder E et al (2008) Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 97:298–305

Hasper D, Hummel M, Kleber FX et al (1998) Systemic inflammation in patients with heart failure. Eur Heart J 19:761–765

Appoloni O, Dupont E, Vandercruys M et al (2004) Association between the TNF-2 allele and a better survival in cardiogenic shock. Chest 125:2232–2237

Malleo G, Mazzon E, Genovese T et al (2008) Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome. Cytokine 41:136–143

Prinsen JH, Baranski E, Posch H et al (2008) Interleukin-6 as diagnostic marker for neonatal sepsis: determination of access IL-6 cutoff for newborns. Clin Lab 54:179–183

Werdan K, Hettwer S, Bubel S et al (2009) Septic circulatory shock and septic cardiomyopathy. Internist (Berl) 50:799–800, 802–806, 808–809

Werdan K, Schmidt H, Ebelt H et al (2009) Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol 87:266–274

Shpektor A (2010) Cardiogenic shock: the role of inflammation. Acute Card Care 12:115–118

TRIUMPH Investigators, Alexander JH, Reynolds HR et al (2007) Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297:1657–1666

Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487–501

Michie HR, Manogue KR, Spriggs DR et al (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486

Levine B, Kalman J, Mayer L et al (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236–241

Suffredini AF, Fromm RE, Parker MM et al (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321:280–287

Reithmann C, Werdan K (1994) Tumor necrosis factor alpha decreases inositol phosphate formation and phosphatidylinositol-bisphosphate (PIP2) synthesis in rat cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 349:175–182

Müller-Werdan U, Schumann H, Loppnow H et al (1998) Endotoxin and tumor necrosis factor alpha exert a similar proinflammatory effect in neonatal rat cardiomyocytes, but have different cardiodepressant profiles. J Mol Cell Cardiol 30:1027–1036

Müller-Werdan U, Engelmann H, Werdan K (1998) Cardiodepression by tumor necrosis factor-alpha. Eur Cytokine Netw 9:689–691

Pestka S (2007) The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 282:20047–20051

Szkodzinski J, Hudzik B, Osuch M et al (2010) Serum concentrations of interleukin-4 and interferon-gamma in relation to severe left ventricular dysfunction in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart Vessels 26:399–407

Metcalf D, Di Rago L, Mifsud S et al (2000) The development of fatal myocarditis and polymyositis in mice heterozygous for IFN-γ and lacking the SOCS-1 gene. Proc Natl Acad Sci U S A 97:9174–9179

Khakoo AY, Halushka MK, Rame JE et al (2005) Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med 2:53–57

Clements JM, Craig S, Gearing AJ et al (1992) Biological and structural properties of MIP-1 alpha expressed in yeast. Cytokine 4:76–82

Broxmeyer HE, Sherry B, Cooper S et al (1993) Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol 150:3448

Roussoulières AL, Raisky O, Chalabreysse L et al (2005) Identification and characterization of two genes (MIP-1beta, VE-CADHERIN) implicated in acute rejection in human heart transplantation: use of murine models in tandem with cDNA arrays. Circulation 111:2626–2644

Roffe E, Souza AL, Caetona BC et al (2006) A DNA vaccine encoding CCL4/MIP-1beta enhances myocarditis in experimental Trypanosoma cruzi infection in rats. Microbes Infect 8(12–13):2745–55

Yadav A, Saini V, Arora S (2010) MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 411:1570–1579

Lemos JA de, Morrow DA, Blazing MA et al (2007) Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes. Results from the A to Z Trial. J Am Coll Cardiol 50:2117–2124

Frangogiannis NG (2007) The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes. J Am Coll Cardiol 50:2125–2127

Shim W, Mehta A, Lim SY et al (2011) G-CSF for stem cell therapy in acute myocardial infarction: friend or foe? Cardiovasc Res 89:20–30

Achilli F, Malafronte C, Lenatti L et al (2010) Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the single-blind, randomized, placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) Trial. Eur J Heart Fail 12:1111–1121

Steppich BA, Demetz G, Schulz S et al (2011) Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. Thromb Res 127:119–121

Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

Altman DA (1991) Practical statistics for medical research. Chapman and Hall, London

Norozi K, Buchhorn R, Wessel A et al (2008) Beta-blockade does not alter plasma cytokine concentrations and ventricular function in young adults with right ventricular dysfunction secondary to operated congenital heart disease. Circ J 72:747–752

Loppnow H, Zhang L, Buerke M et al (2011) Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med 15:994–1004

Sukumaran V, Watanabe K, Veeraveedu PT et al (2011) Olmesartan, an AT(1) antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. Int J Biol Sci 7:154–167

Buys ES, Cauwels A, Raher MJ et al (2009) sGC(alpha)1(beta)1 attenuates cardiac dysfunction and mortality in murine inflammatory shock models. Am J Physiol Heart Circ Physiol 297:H654–663

Hohensinner PJ, Niessner A, Huber K et al (2011) Inflammation and cardiac outcome. Curr Opin Infect Dis 24:259–264

Werra I de, Zanetti G, Jaccard C et al (2001) CD14 expression on monocytes and TNF alpha production in patients with septic shock, cardiogenic shock or bacterial pneumonia. Swiss Med Wkly 131:35–40

Adrie C, Adib-Conquy M, Laurent I et al (2002) Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome. Circulation 106:562–568

Unverzagt S, Machemer M.T, Solms A et al (2011) Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Library:CD007398

Thiele H, Sick P, Boudriot E et al (2005) Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 26:1276–1283

Burkhoff D, Cohen H, Brunckhorst C et al (2006) A randomized multicenter clinical study to evaluate the safety and efficacy of the Tandem Heart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 152:469 (e1–8)

Seyfarth M, Sibbing D, Bauer I et al (2008) A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 52:1584–1588

Jung C, Lauten A, Rödiger C et al (2009) Effect of intra-aortic balloon pump support on microcirculation during high-risk percutaneous intervention. Perfusion 24:417–421